Junhyeong Yim

 

Junhyeong Yim was born in 1991 in Daejeon, Korea. He received his D.V.M. degree in 2016 at Seoul National University. He received his Ph.D. degree in Chemical Biology in 2023. He is now a post-doctoral researcher in Department of Biophysics and Chemical Biology at Seoul National University.

He is interested in proteome profiling and target identification of drug-like small molecules.

Yim, J.; Hwang, Y.S.; Lee, J.-J.; Kim, J.H.; Beak, J.Y.; Jeong J.Y.; Choi, Y.; Jin, B.K.; Park, S.B.* Chem. Sci. 2024, 15, 3588-3595.
Inflachromene ameliorates Parkinson’s disease by targeting Nrf2-binding Keap1.

Cho, W.†; Won, S.†; Choi, Y.; Yi, S.; Park, J.B.; Park, J.-G.; Kim, C.E.; Narayana, C.; Kim, J.H.; Yim, J.; Choi, Y.I.; Lee, D.-S.*; Park, S.B.* Angew. Chem. Int. Ed. 2023, 62, e202300978.
Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy.

Yim, J.; Lee, J.; Yi, S.; Koo, J.Y.; Oh, S.; Park, H.; Kim, S.S.; Bae, M.A.; Park, J.*; Park, S.B.* Exp. Mol. Med 2022, 54, 2200–2209.
Phenotype-based screening rediscovered benzopyran-embedded microtubule inhibitors as anti-neuro inflammatory agents.

Yim, J.; Park, S. B.* Front. Chem. 2022, 10, 850638.
Label-free Target Identification Reveals the Anticancer Mechanism of a Rhenium Isonitrile Complex.

Shin, Y.-H.†; Jung, K.†; Lee, J.; Lee, H.J.; Yim, J.; Kim, J.; Kim, S.*; Park, S. B.* Angew. Chem. Int. Ed. 2022, 61, e2021115695.
Inhibition of ACE2-Spike interaction by ACE2 allosteric binder suppresses SARS-CoV-2 entry.

Hwang, Y.S.†; Yim, J.†; Song, H.†; Park, S. B.* ACS Med. Chem. Lett. 2019, 10, 720-725. († : equally contributed)
Improved Th17 Selectivity of α-Galactosylceramide via Noncovalent Interactions with Diether Moiety.